newsfilter
← Latest News
PR Newswire·

AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update

Divestment of DSUVIA® to Alora Pharmaceuticals expected to close the week of April 3, 2023 AcelRx advancing its proprietary Niyad™ nafamastat program with FDA Breakthrough designation in line with a strategic